All In Biotech

Drug Trial Radar · NCT06197425

Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal Cancer

Phase III Multicentric, Open-label, Randomized Study to Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal Cancer (PRODIGE 88)

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,660 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,660

Planned (sponsor's estimate)

Start

May 7, 2026

Primary completion

May 2032

Study completion May 2032

Sponsor

Lead sponsor
Centre Hospitalier Universitaire DijonAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase III multicentric, open-label, randomized study The main objective is to assess the efficacy on time to disease recurrence (TTR) of treating minimal residual disease diagnosed by the presence of ctDNA after full treatment (surgery + chemotherapy) in stage III or high-risk stage II colon or upper rectum adenocarcinoma

Conditions

  • Colon or Upper Rectum Adenocarcinoma

Interventions

  • "FOLFIRI" curesDrug

    (Irinotecan 180 mg/m2, leucovorine 400mg/m2, 5FU bolus 400 mg/m2, 5FU continuous infusion 2400 mg/m2) every 14 days for 6 months or until disease progression on imaging

  • Trifluridine curesDrug

    Trifluridine tipiracil 35 mg/m2 bid during 5 days/w on week 1 and 2 every 4 weeks, for 6 months or until disease progression on imaging

  • BIOLOGICAL ASSESSMENTBiological

    blood sample ACE markers

  • QuestionnairesOther

    Quality of life questionnaires (QLQ-C30 ; EQ-5D-5L ; GPAQ)

  • Thoracic-abdomino-pelvic scan or MRIOther

    Thoracic-abdomino-pelvic scan or MRI

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The time to recurrence (TTR)Time frame: From date of randomization until the date of first documented progression or date of death from colorectal cancer

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chu Dijon Bourgogne

    Dijon, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.